Search Results - "Kelemen, Cristina Daniela"
-
1
Evaluation of genetic fidelity of in vitro-propagated blackberry plants using RAPD and SRAP molecular markers
Published in Horticultural science (Praha) (01-01-2020)“…The aim of this research was to evaluate the genetic uniformity of blackberry plants (Rubus fruticosus L. ‘Loch Ness’ and ‘Chester Thornless’) obtained by…”
Get full text
Journal Article -
2
Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy
Published in Clinical and translational medicine (01-03-2022)“…A thus far untested approach is targeting mitochondrial respiration using compounds from the group of mitocans,3 epitomised by mitochondrially targeted…”
Get full text
Journal Article -
3
BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo
Published in Blood (15-11-2022)Get full text
Journal Article -
4
Pro-apoptotic Bax and Bak proteins modulate mitochondrial respiration via regulation of TEFM expression
Published in Biochimica et biophysica acta. Bioenergetics (01-09-2024)Get full text
Journal Article -
5
Cell-specific modulation of mitochondrial respiration and metabolism by the pro-apoptotic Bcl-2 family members Bax and Bak
Published in Apoptosis (London) (01-04-2024)“…Proteins from the Bcl-2 family play an essential role in the regulation of apoptosis. However, they also possess cell death-unrelated activities that are less…”
Get full text
Journal Article -
6
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status
Published in Blood advances (09-07-2024)“…•BCL-XL belongs to key factors responsible for inherent and acquired resistance to VEN across diverse BCL2+ lymphoid neoplasms.•Interrupted targeting of BCL-XL…”
Get full text
Journal Article -
7
Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status
Published in Blood advances (07-05-2024)“…Venetoclax, a BCL2 inhibitor, has a promising single-agent activity in mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and large B-cell…”
Get full text
Journal Article